Re-entry planning can help prevent opioid overdose and enable people living with HIV to connect with and stay in care.
Transgender people face discrimination in many facets of life. When it comes to discrimination in clinical settings, it can affect their health for the worse.
A systematic review of research between 2000 and 2016 found no studies of interventions specifically designed to support medication adherence among HIV-positive black women.
Taking more than five medications could be a problem. And many people with HIV are at risk of being on medication overload.
New analysis of the LATTE trial shows the two drugs cabotegravir and rilpivirine may also work as a daily oral formulation, which could be a bridge therapy for people who miss an injectable appointment.
Best Practices for Most Vulnerable Populations: Transgender People, Adolescents, and the Recently Incarcerated
"As we think about the care cascade, we can't even test people [for HIV] to diagnose them if we can't get them in the door to a health care setting," one clinician said.
The combination of dolutegravir and lamivudine is effective for treatment-naive patients regardless of age, gender, or race, according to a new subgroup analysis of the GEMINI clinical studies.
We're covering the latest news and research from this major interdisciplinary meeting on infectious diseases, which takes place in Washington, D.C., from Oct. 2 to Oct. 6.
Researchers reported hopeful news on regimens with lower treatment burdens and newly developed antiretrovirals.
Steven Deeks, M.D., talks about the medical community's hopes, inspirations, and unanswered questions regarding research for an HIV cure.